Synonyms 谷氨酰氨肽酶, Aminopeptidase A, AP-A + [7] |
Introduction Regulates central hypertension through its calcium-modulated preference to cleave N-terminal acidic residues from peptides such as angiotensin II. |
Target |
Mechanism gp160 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism gp160 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism gp160 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date11 Aug 2021 |
Sponsor / Collaborator |
Start Date05 Aug 2021 |
Sponsor / Collaborator Quantum Genomics SA [+1] |
Start Date12 Jul 2021 |
Sponsor / Collaborator |